

PROVEN TO PREVENT MORE CASES OF INFLUENZA IN ADULTS 65+

compared to a standard-dose influenza vaccine in a randomized controlled trial^{1,2,a}.



Influenza Vaccine
Fluzone[®] High-Dose Quadrivalent

PRIMARY ENDPOINT

24% BETTER PROTECTION FROM INFLUENZA
due to any strain

Primary endpoint of the study was the occurrence of laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to vaccine components.

^a The efficacy of Fluzone High-Dose (trivalent formulation) is relevant to Fluzone High-Dose Quadrivalent since both vaccines are manufactured according to the same process and have overlapping compositions.¹

SECONDARY ENDPOINT

51% BETTER PROTECTION FROM INFLUENZA
due to strains antigenically similar to those contained in the vaccine

A secondary endpoint of the study was the occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention–defined influenza-like illness.

SAFETY IN ADULTS 65+

Based on data from Fluzone High-Dose, solicited injection site reactions and systemic adverse reactions were slightly more frequent after vaccination with Fluzone High-Dose compared to a standard-dose vaccine.¹

FLUZONE HIGH-DOSE QUADRIVALENT VACCINE: AVAILABLE FOR THE 2020-2021 INFLUENZA SEASON!

- Helps to protect against 2 influenza A strains and **BOTH INFLUENZA B LINEAGES** that unpredictably co-circulate each season¹
- **0.7-mL DOSE** for intramuscular injection¹
- **4X THE AMOUNT OF ANTIGEN** of a standard-dose quadrivalent inactivated influenza vaccine³
- **SIMILAR SAFETY PROFILE** to Fluzone[®] High-Dose trivalent vaccine¹

Fluzone High-Dose Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

SELECT IMPORTANT SAFETY INFORMATION

Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine.

Please click to see full [Important Safety Information](#).

Please click to see full [Prescribing Information](#) for Fluzone High-Dose Quadrivalent.

**FOR MORE INFORMATION,
PLEASE VISIT SANOFIFLU.COM**

IMPORTANT SAFETY INFORMATION FOR FLUZONE® HIGH-DOSE QUADRIVALENT (INFLUENZA VACCINE)

Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone High-Dose Quadrivalent is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise. Other adverse reactions may occur.

Please see full Prescribing Information.



Fluzone High-Dose Quadrivalent is manufactured and distributed by Sanofi Pasteur Inc.
Fluzone High-Dose Quadrivalent (CPT^{®a} code 90662) is a covered benefit under Medicare Part B.

^aCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

References: **1.** Fluzone High-Dose Quadrivalent [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. **2.** DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med.* 2014;371:635-645. **3.** Sanofi Pasteur Inc. Data on file, 2019. **4.** Sanofi Pasteur Inc. Data on file, 2019.